Navigation Links
Doctors Outraged Over Growth Hormone Controversy

Two anti-aging preventative medicine doctors say they are outraged over recent media coverage about their advocacy of prescribing human growth hormone to treat a hormone deficiency often associated with aging.

DAYTONA BEACH, Fla., April 27, 2007 /PRNewswire/ -- The adult use of human growth hormone (HGH) was at the center of a recent New York Times article about the founders of the American Academy of Anti-Aging Medicine (http://worldhealth.net/), Dr. Ronald Klatz M.D. and Dr. Robert Goldman M.D.

Writing for the New York Times, Duff Wilson reported the two physicians to be promoting the controversial hormone as an aid to extending human life span, despite claimed reports of serious side effects.

In comments to Fintan Dunne, editor of health Web site http://MyLongLife.com, the two physicians say they are outraged by a slew of recent negative media coverage on the topic. MyLongLife.com has a special report with an in-depth examination of the HGH issue and the role of established medical and pharmaceutical interests.

"There is a hidden battle going on for your right to a long, vital and healthy life," says Editor, Fintan Dunne. "Beneath the surface of this story there are hundreds of billions of dollars at stake, along with the future of medicine itself."

Dunne reports that the nascent promise of the anti-aging movement, spearheaded by the American Academy of Anti-Aging Medicine, is to greatly enhance our health as we age. However, he says that is also the worst nightmare of a pharmaceutical industry bent on easing us into premature death with a plethora of profitably expensive medications. "Viewed by entrenched medical interests, the burgeoning development of anti-aging medicine is a potent threat," says Dunne.

The special report on MyLonglife.com asks:

Is HGH real
'"/>




Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
2. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
4. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
5. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
9. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Doctors Outraged Over Growth Hormone Controversy
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5West to Present at Two Upcoming Investor Conferences 56960 1West to Present at Two Upcoming Investor Conferences 56960 2Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2